PLSEPULSE BIOSCIENCES, INC.
Surgical & Medical Instruments & Apparatus
- Revenue
- $350K
- Operating margin
- -21982.6%
- EBITDA
- −$77M
- 37% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired61× of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear2% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1M | $700K | $0 | $0 | $350K | |
| Operating income | −$63M | −$58M | −$44M | −$56M | −$77M | 37% |
| Net income | −$64M | −$59M | −$42M | −$54M | −$73M | 36% |
| Operating cash flow | −$54M | −$47M | −$33M | −$36M | −$54M | 49% |
| Capex | $437K | $401K | $121K | $125K | $315K | 152% |
| Stock-based comp | $15M | $5M | $7M | $14M | $21M | 58% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 58 | — |
| FY2024 | — | — | 73 | — |
| FY2023 | — | — | 51 | — |
| FY2022 | $424K | −$194K | 12 | — |